Gene info: ID 100

Gene: ADA

GENE ID: 100

Synonyms: -

Description: adenosine deaminase

Gene type: protein-coding

Location: 20q13.12

dbXrefs: Ensembl:ENSG00000196839 MIM:608958 Vega:OTTHUMG00000033081 UniprotKB:P00813

RefSeq: NG_007385.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: OD|ND|AD

# Publications: 22

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.771e-1 (AD) 1.751e-3 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PLEKHF1	0.787
RRBP1	0.782
VWA1	0.753
CDC42EP1	0.748
CD82	0.745
LITAF	0.74
RHOG	0.739
TNFAIP6	0.738
LMNA	0.732
TFEB	0.728

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CNTN5	-0.452
F7	-0.446
NEK10	-0.445
NDST3	-0.442
ST6GALNAC5	-0.44
KCNQ4	-0.439
CDH8	-0.436
CDH7	-0.433
CHRM4	-0.432
BFSP1	-0.43

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00552	Pentostatin	Small Molecule	53910-25-1	Approved\|Investigational	Target
DB00975	Dipyridamole	Small Molecule	58-32-2	Approved	Target
DB02096	FR221647	Small Molecule	-	Experimental	Target
DB02472	6-Hydroxy-7,8-Dihydro Purine Nucleoside	Small Molecule		Experimental	Target
DB02616	FR117016	Small Molecule		Experimental	Target
DB02830	FR236913	Small Molecule		Experimental	Target
DB03015	6-Hydroxy-1,6-Dihydro Purine Nucleoside	Small Molecule		Experimental	Target
DB03220	FR233623	Small Molecule		Experimental	Target
DB03370	FR239087	Small Molecule		Experimental	Target
DB03572	FR230513	Small Molecule		Experimental	Target
DB04218	1-Deaza-Adenosine	Small Molecule		Experimental	Target
DB04440	Nebularine	Small Molecule	550-33-4	Experimental	Target
DB07711	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol	Small Molecule		Experimental	Target
DB07783	1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE	Small Molecule		Experimental	Target
DB07785	1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE	Small Molecule		Experimental	Target
DB07786	1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE	Small Molecule		Experimental	Target
DB00194	Vidarabine	Small Molecule	24356-66-9	Approved\|Investigational	Enzyme
DB00277	Theophylline	Small Molecule	58-55-9	Approved	Enzyme
DB00640	Adenosine	Small Molecule	58-61-7	Approved\|Investigational	Enzyme
DB00974	Edetic Acid	Small Molecule	60-00-4	Approved	Enzyme
DB01280	Nelarabine	Small Molecule	121032-29-9	Approved\|Investigational	Enzyme
DB05057	Erdosteine	Small Molecule	84611-23-4	Investigational	Enzyme

ID	Drug Name	Action	PubMed
C025223	1,4-dioxane	"1,4-dioxane affects the activity of ADA protein"	11583161
C548651	2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of ADA mRNA	19933214
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ADA mRNA"	19114083
C001073	2,4-dinitrobenzenesulfonic acid	"2,4-dinitrobenzenesulfonic acid results in increased expression of ADA mRNA"	20860664
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of ADA mRNA"	21346803
C058118	2'-deoxyadenosine	ADA protein results in decreased amination of 2'-deoxyadenosine	21138280
C472791	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of ADA mRNA	16788091
C017906	3-dinitrobenzene	3-dinitrobenzene binds to [ADA protein binds to Adenosine]	22106038
C017906	3-dinitrobenzene	3-dinitrobenzene binds to and results in decreased activity of ADA protein	22106038
C568342	3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one	3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one results in decreased activity of ADA protein	21172326
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in decreased expression of ADA mRNA"	25380136
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C010192	9-(2-hydroxy-3-nonyl)adenine	9-(2-hydroxy-3-nonyl)adenine results in decreased activity of ADA protein	17696452\|2113828
C496492	abrine	abrine results in increased expression of ADA mRNA	22595364
D000082	Acetaminophen	Acetaminophen results in decreased expression of ADA mRNA	29067470
D000082	Acetaminophen	Acetaminophen affects the expression of ADA mRNA	17562736
D000082	Acetaminophen	Acetaminophen results in decreased expression of ADA mRNA	17585979
D000241	Adenosine	ADA alternative form results in decreased metabolism of Adenosine	16221767
D000241	Adenosine	ADA protein results in increased metabolism of Adenosine	16221767
D000241	Adenosine	3-dinitrobenzene binds to [ADA protein binds to Adenosine]	22106038
D000241	Adenosine	ADA protein results in decreased amination of Adenosine	21138280
D000241	Adenosine	ADA protein results in increased metabolism of Adenosine	22106038
D000241	Adenosine	Adenosine analog results in decreased activity of ADA protein	21138280
D000324	Adrenocorticotropic Hormone	Adrenocorticotropic Hormone results in increased activity of ADA protein	8868375
C016601	afimoxifene	afimoxifene results in decreased expression of ADA mRNA	19901195
C068073	Am 580	Am 580 results in increased expression of ADA mRNA	16982809
C018824	ammonium acetate	ammonium acetate results in increased activity of ADA protein	19900420
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ADA mRNA	16483693
D001280	Atrazine	Atrazine results in increased expression of ADA mRNA	22378314
C487081	belinostat	belinostat results in decreased expression of ADA mRNA	26272509\|2718838
C487081	belinostat	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
D001554	Benzene	Benzene results in decreased activity of ADA protein	17562280
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of ADA mRNA	26377693
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ADA mRNA	20106945\|2163298
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of ADA mRNA	21569818
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased activity of ADA protein	18057710
D001564	Benzo(a)pyrene	Quercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of ADA protein]	18057710
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in increased expression of ADA mRNA	20660070
C044887	beta-methylcholine	beta-methylcholine affects the expression of ADA mRNA	21179406
C006780	bisphenol A	bisphenol A results in increased methylation of ADA promoter	27312807
C006780	bisphenol A	bisphenol A affects the expression of ADA mRNA	25181051
C000611646	bisphenol F	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA	28628672
D019256	Cadmium Chloride	Cadmium Chloride results in increased activity of ADA protein	25064450
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of ADA promoter	22457795
D019256	Cadmium Chloride	Quercetin inhibits the reaction [Cadmium Chloride results in increased activity of ADA protein]	25064450
C055494	caffeic acid phenethyl ester	caffeic acid phenethyl ester inhibits the reaction [Methotrexate results in increased activity of ADA protein]	16325979
D002110	Caffeine	Caffeine results in increased expression of ADA protein	6149265
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased activity of ADA protein	19900420
D002737	Chloroprene	Chloroprene results in decreased expression of ADA mRNA	23125180
C031180	chrysene	chrysene results in increased expression of ADA mRNA	26377693
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of ADA mRNA	19320972
C018021	cobaltous chloride	cobaltous chloride results in increased expression of ADA mRNA	19376846
C018021	cobaltous chloride	cobaltous chloride results in increased expression of ADA mRNA	24386269
D003070	Coformycin	Coformycin binds to and results in decreased activity of ADA protein	21138280
D003471	Cuprizone	Cuprizone results in increased expression of ADA mRNA	26577399
D016572	Cyclosporine	Cyclosporine results in increased expression of ADA mRNA	25562108
C014347	decitabine	decitabine affects the expression of ADA mRNA	23300844
D015649	Pentostatin	Pentostatin binds to and results in decreased activity of ADA protein	21138280
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA	28628672
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of ADA mRNA	17361019\|2126653
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of ADA mRNA	21266533
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of ADA mRNA	24893172
D002945	Cisplatin	Cisplatin affects the expression of ADA mRNA	23300844
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of ADA mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of ADA mRNA	27392435
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in decreased expression of ADA mRNA	25380136
D004229	Dithiothreitol	Dithiothreitol inhibits the reaction [Mercuric Chloride results in decreased activity of ADA protein]	20226812
D004317	Doxorubicin	Doxorubicin results in increased activity of ADA protein	12965118
D004317	Doxorubicin	erdosteine inhibits the reaction [Doxorubicin results in increased activity of ADA protein]	12965118
D004318	Doxycycline	Doxycycline inhibits the reaction [Isoproterenol results in increased expression of ADA mRNA]	18089841
C118739	entinostat	entinostat results in increased expression of ADA mRNA	27188386
C048498	erdosteine	erdosteine inhibits the reaction [Doxorubicin results in increased activity of ADA protein]	12965118
D000431	Ethanol	Ethanol affects the activity of ADA protein	11583161
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ADA mRNA	17555576\|1794274
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ADA mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ADA mRNA	17557909
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of ADA mRNA	23649840
C082360	fipronil	fipronil results in increased expression of ADA mRNA	23962444
D005485	Flutamide	Flutamide results in increased expression of ADA mRNA	24793618
D009240	N-Formylmethionine Leucyl-Phenylalanine	ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]	10947063
D019833	Genistein	Genistein results in decreased activity of ADA protein	7853360
D019833	Genistein	Tetrachlorodibenzodioxin inhibits the reaction [Genistein results in decreased activity of ADA protein]	7853360
D005990	Glycerol	[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol	17428236
D017313	Fenretinide	Fenretinide results in increased expression of ADA mRNA	28973697
C492448	ICG 001	ICG 001 results in decreased expression of ADA mRNA	26191083
C014612	indolebutyric acid	indolebutyric acid results in decreased activity of ADA protein	19442822
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA	28628672
D007288	Inosine	ADA alternative form results in decreased abundance of Inosine	16221767
D007288	Inosine	ADA protein results in increased abundance of Inosine	16221767
C051890	irinotecan	irinotecan affects the expression of ADA mRNA	20097248
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA	28628672
D007545	Isoproterenol	Doxycycline inhibits the reaction [Isoproterenol results in increased expression of ADA mRNA]	18089841
D007545	Isoproterenol	Isoproterenol results in increased expression of ADA mRNA	18089841\|2000320
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of ADA mRNA	27392435
C544151	jinfukang	jinfukang results in increased expression of ADA mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of ADA mRNA	26752646
D008627	Mercuric Chloride	Dithiothreitol inhibits the reaction [Mercuric Chloride results in decreased activity of ADA protein]	20226812
D008627	Mercuric Chloride	Mercuric Chloride results in decreased activity of ADA protein	20226812
D000432	Methanol	Methanol affects the activity of ADA protein	11583161
D008727	Methotrexate	caffeic acid phenethyl ester inhibits the reaction [Methotrexate results in increased activity of ADA protein]	16325979
D008727	Methotrexate	Methotrexate results in increased activity of ADA protein	16325979
D008727	Methotrexate	Methotrexate metabolite results in decreased activity of ADA protein	25575725
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of ADA mRNA	23458150
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of ADA mRNA	20375079
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of ADA mRNA	26011545
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of ADA mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of ADA mRNA"	25554681\|2562005
C031721	naphthalene	naphthalene results in increased expression of ADA mRNA	18978301
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in decreased expression of ADA mRNA	25380136
C005248	nebularine	nebularine analog results in decreased activity of ADA protein	21138280
C005248	nebularine	nebularine analog results in decreased activity of ADA protein	21138280
C005248	nebularine	nebularine results in decreased activity of ADA protein	21138280
D009355	Neomycin	Neomycin results in decreased activity of ADA protein	7853360
D009355	Neomycin	Tetrachlorodibenzodioxin inhibits the reaction [Neomycin results in decreased activity of ADA protein]	7853360
C029938	nickel sulfate	nickel sulfate results in increased expression of ADA mRNA	22714537
D009534	Niclosamide	Niclosamide results in increased expression of ADA mRNA	26452273
D009638	Norepinephrine	[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol	17428236
D009638	Norepinephrine	ADA protein results in decreased susceptibility to Norepinephrine	7949234
D009638	Norepinephrine	Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine]	7949234
C030110	oxaliplatin	oxaliplatin results in decreased expression of ADA mRNA	17762391
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in increased expression of ADA mRNA	25729387
C030110	oxaliplatin	oxaliplatin results in increased expression of ADA mRNA	25729387
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C496932	panobinostat	panobinostat results in decreased expression of ADA mRNA	26272509
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of ADA mRNA	28973697
D010634	Phenobarbital	NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of ADA mRNA]	19482888
D010634	Phenobarbital	Phenobarbital affects the expression of ADA mRNA	23091169
D010634	Phenobarbital	Phenobarbital results in decreased expression of ADA mRNA	19482888
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of ADA mRNA	26272509
C006253	pirinixic acid	pirinixic acid results in decreased expression of ADA mRNA	17426115
D010936	Plant Extracts	Plant Extracts results in increased expression of ADA mRNA	23557933
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of ADA mRNA	22714537
D011374	Progesterone	Progesterone results in decreased expression of ADA mRNA	23018184
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in increased expression of ADA mRNA	20660070
D011433	Propranolol	Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine]	7949234
D011441	Propylthiouracil	Propylthiouracil results in increased expression of ADA mRNA	24780913
D011794	Quercetin	Quercetin results in increased expression of ADA mRNA	21632981
D011794	Quercetin	[Quercetin co-treated with Tetrachlorodibenzodioxin] results in decreased activity of ADA protein	7853360
D011794	Quercetin	Quercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of ADA protein]	18057710
D011794	Quercetin	Quercetin results in decreased activity of ADA protein	7853360
D011794	Quercetin	Tetrachlorodibenzodioxin inhibits the reaction [Quercetin results in decreased activity of ADA protein]	7853360
D011794	Quercetin	Quercetin inhibits the reaction [Cadmium Chloride results in increased activity of ADA protein]	25064450
D011794	Quercetin	Quercetin results in decreased activity of ADA protein	25064450
C089730	rosiglitazone	rosiglitazone results in increased expression of ADA mRNA	16982809
C541923	sandostatinLAR	sandostatinLAR results in increased expression of ADA mRNA	17210224
C017947	sodium arsenite	sodium arsenite affects the expression of ADA mRNA	20816728
D053260	Soot	Soot results in increased expression of ADA mRNA	26551751
D013395	Sucrose	Sucrose affects the activity of ADA protein	11583161
D013481	Superoxides	ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]	10947063
C061133	tamibarotene	tamibarotene results in increased expression of ADA mRNA	15498508
D013629	Tamoxifen	Tamoxifen affects the expression of ADA mRNA	17555576
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of ADA mRNA	19901195
D013749	Tetrachlorodibenzodioxin	[Quercetin co-treated with Tetrachlorodibenzodioxin] results in decreased activity of ADA protein	7853360
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ADA mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ADA mRNA	17942748
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of ADA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Genistein results in decreased activity of ADA protein]	7853360
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Neomycin results in decreased activity of ADA protein]	7853360
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Quercetin results in decreased activity of ADA protein]	7853360
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased activity of ADA protein	7853360
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of ADA mRNA	19933214
C009495	titanium dioxide	titanium dioxide results in increased expression of ADA mRNA	23409001
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in increased expression of ADA mRNA	25729387
D014118	Toxins, Biological	"Toxins, Biological affects the expression of ADA mRNA"	19682533
D014212	Tretinoin	Tretinoin results in increased expression of ADA mRNA	15498508\|1589460
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of ADA mRNA	26272509
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of ADA mRNA	19042947
C013320	tris(2-butoxyethyl) phosphate	tris(2-butoxyethyl) phosphate affects the expression of ADA mRNA	29024780
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of ADA mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of ADA mRNA	23179753\|2627250
D014638	Vanadates	Vanadates results in increased expression of ADA mRNA	22714537
D002762	Cholecalciferol	Cholecalciferol results in decreased expression of ADA mRNA	16508948
C111237	vorinostat	vorinostat results in decreased expression of ADA protein	20543569
D015215	Zidovudine	Zidovudine results in increased expression of ADA protein	2261134

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001883	purine nucleoside binding	-	IEA	-
GO:0004000	adenosine deaminase activity	-	EXP	3182793
GO:0004000	adenosine deaminase activity	-	IBA	21873635
GO:0004000	adenosine deaminase activity	-	IDA	3182793 8452534 8894685 9361033 11999881 16670267
GO:0004000	adenosine deaminase activity	-	ISS	-
GO:0005515	protein binding	-	IPI	7594462 8101391 14684150
GO:0008270	zinc ion binding	-	IMP	7599635
GO:0008270	zinc ion binding	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001666	response to hypoxia	-	IDA	16670267
GO:0001821	histamine secretion	-	IEA	-
GO:0001829	trophectodermal cell differentiation	-	IEA	-
GO:0001889	liver development	-	IEA	-
GO:0001890	placenta development	-	IEA	-
GO:0002314	germinal center B cell differentiation	-	IEA	-
GO:0002636	positive regulation of germinal center formation	-	IEA	-
GO:0002686	negative regulation of leukocyte migration	-	IEA	-
GO:0002906	negative regulation of mature B cell apoptotic process	-	IEA	-
GO:0006154	adenosine catabolic process	-	IBA	21873635
GO:0006154	adenosine catabolic process	-	IDA	8894685 16670267
GO:0006154	adenosine catabolic process	-	ISS	-
GO:0006157	deoxyadenosine catabolic process	-	IEA	-
GO:0007155	cell adhesion	-	IEA	-
GO:0007568	aging	-	IEA	-
GO:0009168	purine ribonucleoside monophosphate biosynthetic process	-	IEA	-
GO:0010460	positive regulation of heart rate	-	IEA	-
GO:0030890	positive regulation of B cell proliferation	-	IEA	-
GO:0032261	purine nucleotide salvage	-	IMP	9361033
GO:0033089	positive regulation of T cell differentiation in thymus	-	IEA	-
GO:0033197	response to vitamin E	-	IEA	-
GO:0033632	regulation of cell-cell adhesion mediated by integrin	-	IDA	11772392
GO:0042110	T cell activation	-	IBA	21873635
GO:0042110	T cell activation	-	IDA	7594462
GO:0042323	negative regulation of circadian sleep/wake cycle, non-REM sleep	-	IEA	-
GO:0042542	response to hydrogen peroxide	-	IEA	-
GO:0043101	purine-containing compound salvage	-	TAS	-
GO:0043103	hypoxanthine salvage	-	IBA	21873635
GO:0043278	response to morphine	-	IEA	-
GO:0045987	positive regulation of smooth muscle contraction	-	IEA	-
GO:0046061	dATP catabolic process	-	IEA	-
GO:0046103	inosine biosynthetic process	-	IBA	21873635
GO:0046103	inosine biosynthetic process	-	IDA	8894685
GO:0046103	inosine biosynthetic process	-	ISS	-
GO:0046111	xanthine biosynthetic process	-	IEA	-
GO:0046638	positive regulation of alpha-beta T cell differentiation	-	IEA	-
GO:0048286	lung alveolus development	-	IEA	-
GO:0048541	Peyer's patch development	-	IEA	-
GO:0048566	embryonic digestive tract development	-	IEA	-
GO:0050728	negative regulation of inflammatory response	-	IEA	-
GO:0050850	positive regulation of calcium-mediated signaling	-	IEA	-
GO:0050862	positive regulation of T cell receptor signaling pathway	-	IEA	-
GO:0060169	negative regulation of adenosine receptor signaling pathway	-	IBA	21873635
GO:0060169	negative regulation of adenosine receptor signaling pathway	-	IDA	16670267
GO:0060407	negative regulation of penile erection	-	IEA	-
GO:0070244	negative regulation of thymocyte apoptotic process	-	IEA	-
GO:0070256	negative regulation of mucus secretion	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005615	extracellular space	-	IEA	-
GO:0005764	lysosome	-	IDA	8452534
GO:0005829	cytosol	-	IBA	21873635
GO:0005829	cytosol	-	IDA	-
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IDA	-
GO:0009897	external side of plasma membrane	-	IBA	21873635
GO:0009897	external side of plasma membrane	-	IDA	7759315 16670267
GO:0009986	cell surface	-	IDA	7594462 11772392
GO:0016020	membrane	-	IDA	11999881
GO:0030054	cell junction	-	IEA	-
GO:0032839	dendrite cytoplasm	-	IEA	-
GO:0043025	neuronal cell body	-	IEA	-
GO:0060205	cytoplasmic vesicle lumen	-	IEA	-

KEGG ID	KEGG Term
hsa00230	Purine metabolism
hsa01100	Metabolic pathways
hsa05340	Primary immunodeficiency

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-15869	Metabolism of nucleotides	TAS
R-HSA-74217	Purine salvage	TAS
R-HSA-8956321	Nucleotide salvage	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
14560041	Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. (2003 Dec)	Ho WZ	J Pharmacol Exp Ther
25812364	[Biguanide]. (2015 Mar)	Ohta A	Nihon Rinsho
27437997	Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study. (2016)	Hu H	PLoS One
16128225	The relation of the pleural thickening in tuberculosis pleurisy with the activity of adenosine deaminase. (2005 Jun)	Uskul B	Monaldi Arch Chest Dis
18562134	ADA genetic polymorphism and the effect of smoking on neonatal bilirubinemia and developmental parameters. (2008 Nov)	Gloria-Bottini F	Early Hum Dev
21608352	Prevalence of diabetes mellitus in a rural population of Goa, India. (2011 Jan-Feb)	Vaz NC	Natl Med J India
23583988	An increased circulating angiotensin II concentration is associated with hypoadiponectinemia and postprandial hyperglycemia in men with nonalcoholic fatty liver disease. (2013)	Xu YZ	Intern Med
16026378	Clustering of protective factors for glucose intolerance and insulin resistance: a cross-sectional study. (2005 Aug)	Perry IJ	Diabet Med
27557561	Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. (2016 Aug 24)	Maneechotesuwan K	Respir Res
23808735	[Up to day trends in insulin therapy]. (2013 Jun)	Adamikova A	Vnitr Lek
27596362	Caffeine plus nicotine improves motor function, spatial and non-spatial working memory and functional indices in BALB/c male mice. (2016 Dec)	Adeniyi PA	Pathophysiology
20445731	[Malignant peritoneal mesothelioma]. (2010 Jan-Mar)	Torrejon Reyes PN	Rev Gastroenterol Peru
25503445	Fasting blood glucose, but not 2-h postload blood glucose or HbA1c, is associated with mild decline in estimated glomerular filtration rate in healthy Chinese. (2015 Jan)	Sun Y	Int Urol Nephrol
11521552	Disability insurance--ADA--benefits for mental disability, alcoholism and drug abuse. Weyer v. Twentieth Century Fox Film Corp., 198 F.3d 1104 (9th Cir. 2000). (2001)	-	Benefits Q
26486189	Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans. (2015 Dec)	Eastwood SV	Diabetes Care
15048173	Role of HbA1c in management of diabetes mellitus. (2004 Mar)	Al-Ghamdi AA	Saudi Med J
28321313	Correlation study of adenosine deaminase and its isoenzymes in type 2 diabetes mellitus. (2017)	Sapkota LB	BMJ Open Diabetes Res Care
28683240	PREVALENCE OF DIABETES IN GREATER BEIRUT AREA: WORSENING OVER TIME. (2017 Sep)	Nasrallah MP	Endocr Pract
27838211	Chronic alcohol administration affects purine nucleotide catabolism in vivo. (2017 Jan 1)	Zhang JD	Life Sci
18807734	How frequently the clinical practice recommendations for nephropathy are achieved in patients with type 2 diabetes mellitus in a primary health-care setting? (2008 May-Jun)	Martinez-Ramirez HR	Rev Invest Clin
24762755	Factors influencing pleural adenosine deaminase level in patients with tuberculous pleurisy. (2014 Nov)	Lee SJ	Am J Med Sci
26864064	Inflammation markers are associated with metabolic syndrome and ventricular arrhythmia in patients with coronary artery disease. (2016 Feb 11)	Safranow K	Postepy Hig Med Dosw (Online)